Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid Tumors

NCT03154294 is registered in ClinicalTrials.gov with Avera McKennan Hospital & University Health Center as lead sponsor.

NCT NCT03154294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03154294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid Tumors
Lead sponsor
Avera McKennan Hospital & University Health Center
Phase
Phase 1
Overall status
Completed
Start date
July 6, 2017
Completion date
November 20, 2022
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor